Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 8, 2013, Pages 1227-1240

  Dixit, Anubhuti ^a   Srivastava, Garima ^a   Verma, Divya ^a   Mishra, Manisha ^b   Singh, Pradhyumna Kumar ^b   Prakash, Om ^c   Singh, Mahendra Pratap ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b CSIR NATIONAL BOTANICAL RESEARCH INSTITUTE   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Levodopa; Manganese (III) tetrakis (1 methyl 4 pyridyl) porphyrin; Minocycline; Mitochondrial proteome; Parkinsonism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; LACTATE DEHYDROGENASE; LEVODOPA; MANEB; MANGANESE (III) TETRAKIS (1 METHYL 4 PYRIDYL)PORPHYRIN; MANGANESE SUPEROXIDE DISMUTASE; MINOCYCLINE; PARAQUAT; PORPHYRIN; PORPHYRIN DERIVATIVE; PROTEOME; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; MALE; MASS SPECTROMETRY; MICROGLIA; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATONIGRAL DEGENERATION; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; HOMEODOMAIN PROTEINS; LEVODOPA; MALE; MANEB; METALLOPORPHYRINS; MICE; MICROGLIA; MINOCYCLINE; MITOCHONDRIA; PARAQUAT; PARKINSON DISEASE, SECONDARY; PROTEOME; STATHMIN; SUPEROXIDE DISMUTASE;

EID: 84877328104     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.03.019     Document Type: Article

References (64)

1. Dauer W., Przedborski S. Parkinson's disease: review mechanisms and models. Neuron 2003, 39:889-909.
2. Yadav S., Dixit A., Agrawal S., Singh A., Srivastava G., Singh A.K., Srivastava P.K., Prakash O., Singh M.P. Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis. Mol. Neurobiol. 2012, 46:495-512.
3. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., Andersen S.L., Stephens R.M., Benes F.M., Sonntag K.C. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132:1795-1809.
4. Diao H., Li X., Hu S. The identification of dysfunctional crosstalk of pathways in Parkinson disease. Gene 2013, 155:159-162.
5. Mizuno Y., Sone N., Saitoh T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 1987, 48:1787-1793.
6. Cochemé H.M., Murphy M.P. Complex I is the major site of mitochondrial superoxide production by paraquat. J. Biol. Chem. 2008, 283:1786-1798.
7. Singhal N.K., Srivastava G., Agrawal S., Jain S.K., Singh M.P. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?. Mol. Neurobiol. 2012, 45:186-199.
8. +, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys. 1987, 259:645-649.
9. Arduíno D.M., Esteves A.R., Oliveira C.R., Cardoso S.M. Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9:105-119.
10. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch. Neurol. 2010, 67:1442-1448.
11. Singh A.K., Tiwari M.N., Dixit A., Upadhyay G., Patel D.K., Singh D., Prakash O., Singh M.P. Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation-dependent and -independent regulations. Toxicol. Sci. 2011, 122:526-538.
12. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 2007, 25:392-400.
13. Lipski J., Nistico R., Berretta N., Guatteo E., Bernardi G., Mercuri N.B. l-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?. Prog. Neurobiol. 2011, 94:389-407.
14. Shin J.Y., Park H.J., Ahn Y.H., Lee P.H. Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J. Neurochem. 2009, 111:1042-1050.
15. McCormack A.L., Di Monte D.A. Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J. Neurochem. 2003, 85:82-86.
16. Tsironis C., Marselos M., Evangelou A., Konitsiotis S. The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary?. Mov. Disord. 2008, 23:950-957.
17. Patki G., Lau Y.S. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 2011, 99:704-711.
18. de la Torre M.R., Casado A., López-Fernández M.E., Carrascosa D., Casado M.C., Venarucci D., Venarucci V. Human aging brain disorders: role of antioxidant enzymes. Neurochem. Res. 1996, 21:885-888.
19. Liang L.P., Huang J., Fulton R., Day B.J., Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J. Neurosci. 2007, 27:4326-4333.
20. Chen P., Chen Z., Li A., Lou X.C., Wu X.K., Zhao C.J., Wang S.L., Liang L.P. Catalytic metalloporphyrin protects against paraquat neurotoxicity in vivo. Biomed. Environ. Sci. 2008, 21:233-238.
21. Wang T., Liu B., Qin L., Wilson B., Hong J.S. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal-glial cultures. J. Neuroimmunol. 2004, 147:68-72.
22. Pickrell A.M., Pinto M., Hida A., Moraes C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2011, 31:17649-17658.
23. Huang C.L., Lee Y.C., Yang Y.C., Kuo T.Y., Huang N.K. Minocycline prevents paraquat-induced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. Toxicol. Lett. 2012, 209:203-210.
24. Burté F., De Girolamo L.A., Hargreaves A.J., Billett E.E. Alterations in the mitochondrial proteome of neuroblastoma cells in response to complex 1 inhibition. J. Proteome Res. 2011, 10:1974-1986.
25. Liu B., Shi Q., Ma S. Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice. Biochem. Biophys. Res. Commun. 2008, 376:277-282.
26. Jin J., Meredith G.E., Chen L., Zhou Y., Xu J., Shie F.S., Lockhart P., Zhang J. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:119-138.
27. Srivastava G., Dixit A., Yadav S., Patel D.K., Prakash O., Singh M.P. Resveratrol potentiates cytochrome P450 2d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic. Biol. Med. 2012, 52:1294-1306.
28. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74:721-729.
29. Patel S., Sinha A., Singh M.P. Identification of differentially expressed proteins in striatum of maneb- and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol. Teratol. 2007, 29:578-585.
30. Gerlach M., van den Buuse M., Blaha C., Bremen D., Riederer P. Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:388-394.
31. Sharma S.D., Raghuraman G., Lee M.S., Prabhakar N.R., Kumar G.K. Intermittent hypoxia activates peptidylglycine alpha-amidating monooxygenase in rat brain stem via reactive oxygen species-mediated proteolytic processing. J. Appl. Physiol. 2009, 106:12-19.
32. Andrews Z.B., Horvath B., Barnstable C.J., Elsworth J., Yang L., Beal M.F., Roth R.H., Matthews R.T., Horvath T.L. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J. Neurosci. 2005, 25:184-191.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
34. Karunakaran S., Diwakar L., Saeed U., Agarwal V., Ramakrishnan S., Iyengar S., Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 2007, 21:2226-2236.
35. Daley E., Wilkie D., Loesch A., Hargreaves I.P., Kendall D.A., Pilkington G.J., Bates T.E. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem. Biophys. Res. Commun. 2005, 328:623-632.
36. Gevaerd M.S., Miyoshi E., Silveira R., Canteras N.S., Takahashi R.N., Da Cunha C. l-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int. J. Neuropsychopharmacol. 2001, 4:361-370.
37. Perry T.L., Yong V.W., Ito M., Foulks J.G., Wall R.A., Godin D.V., Clavier R.M. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of l-DOPA and carbidopa chronically. J. Neurochem. 1984, 43:990-993.
38. Allen E., Carlson K.M., Zigmond M.J., Cavanaugh J.E. l-DOPA reverses motor deficits associated with normal aging in mice. Neurosci. Lett. 2011, 489:1-4.
39. Inamdar A.A., Chaudhuri A., O'Donnell J. The protective effect of minocycline in a paraquat-induced Parkinson's disease model in Drosophila is modified in altered genetic backgrounds. Parkinsons. Dis. 2012, 2012:938528.
40. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006, 96:706-718.
41. Jung B.D., Shin E.J., Nguyen X.K., Jin C.H., Bach J.H., Park S.J., Nah S.Y., Wie M.B., Bing G., Kim H.C. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem. Int. 2010, 56:229-244.
42. Roede J.R., Hansen J.M., Go Y.M., Jones D.P. Maneb and paraquat-mediated neurotoxicity: involvement of peroxiredoxin/thioredoxin system. Toxicol. Sci. 2011, 121:368-375.
43. Tangpong J., Sompol P., Vore M., St Clair W., Butterfield D.A., St Clair D.K. Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 2008, 151:622-629.
44. Williams M.D., Van Remmen H., Conrad C.C., Huang T.T., Epstein C.J., Richardson A. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J. Biol. Chem. 1998, 273:28510-28515.
45. +-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol. 2009, 29:1169-1180.
46. Yao L., Li W., She H., Dou J., Jia L., He Y., Yang Q., Zhu J., Cápiro N.L., Walker D.I., Pennell K.D., Pang Y., Liu Y., Han Y., Mao Z. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J. Biol. Chem. 2012, 287:34246-34255.
47. Liou A.K., Zhou Z., Pei W., Lim T.M., Yin X.M., Chen J. BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP. FASEB J. 2005, 10:191350-191352.
48. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., Torp R., Torgner I.A., Ottersen O.P., Dawson T.M., Dawson V.L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 2005, 14:2063-2073.
49. Diedrich M., Mao L., Bernreuther C., Zabel C., Nebrich G., Kleene R., Klose J. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics 2008, 8:1266-1275.
50. Lessner G., Schmitt O., Haas S.J., Mikkat S., Kreutzer M., Wree A., Glocker M.O. Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. J. Proteome Res. 2010, 9:4671-4687.
51. Butterfield D.A., Lange M.L. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 2009, 111:915-933.
52. Yan X., Liu T., Yang S., Ding Q., Liu Y., Zhang X., Que H., Wei K., Luo Z., Liu S. Proteomic profiling of the insoluble pellets of the transected rat spinal cord. J. Neurotrauma 2009, 26:179-193.
53. Kobayashi T., Matsumine H., Matuda S., Mizuno Y. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann. Neurol. 1998, 43:120-123.
54. Stacpoole P.W., Owen R., Flotte T.R. The pyruvate dehydrogenase complex as a target for gene therapy. Curr. Gene Ther. 2003, 3:239-245.
55. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967:152-160.
56. Qu D., Rashidian J., Mount M.P., Aleyasin H., Parsanejad M., Lira A., Haque E., Zhang Y., Callaghan S., Daigle M., Rousseaux M.W., Slack R.S., Albert P.R., Vincent I., Woulfe J.M., Park D.S. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 2007, 55:37-52.
57. Gavet O., El Messari S., Ozon S., Sobel A. Regulation and subcellular localization of the microtubule-destabilizing stathmin family phosphoproteins in cortical neurons. J. Neurosci. Res. 2002, 68:535-550.
58. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 2002, 82:1524-1532.
59. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 2003, 85:1394-1401.
60. Spiliotis E.T., Nelson W.J. Here come the septins: novel polymers that coordinate intracellular functions and organization. J. Cell Sci. 2006, 119:4-10.
61. Gollamudi S., Johri A., Calingasan N.Y., Yang L., Elemento O., Beal M.F. Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS One 2012, 7:e36191.
62. Liu Z., Meray R.K., Grammatopoulos T.N., Fredenburg R.A., Cookson M.R., Liu Y., Logan T., Lansbury P.T. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4635-4640.
63. Lee W., Choi K.S., Riddell J., Ip C., Ghosh D., Park J.H., Park Y.M. Human peroxiredoxin 1 and 2 are not duplicate proteins: the unique presence of CYS83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2. J. Biol. Chem. 2007, 282:22011-22022.
64. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13632-13637.